CanSino Biologics Inc
Research CanSino Biologics Inc (CJH) on Bullrun: market cap EUR 563.26M, P/E 228.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCJH
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 563.26M
- P/E228.0
- Financial periodFY2025
- RevenueEUR 1.06B
- Revenue growth28.4%
- Net incomeEUR 27.87M
- Free cash flow-EUR 166.04M
- Gross margin75.4%
Valuation Snapshot
latest market cap is EUR 563.26M; P/E is 228.0.
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
Frequently asked questions
What is CanSino Biologics Inc's market cap?
CanSino Biologics Inc's market capitalization is EUR 563.26M.
What is CanSino Biologics Inc's P/E ratio?
CanSino Biologics Inc's price-to-earnings (P/E) ratio is 228.0.
What does CanSino Biologics Inc do?
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine;